## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%); PEG 2.26 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($48.07)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. BioNTech And Bristol’s Pumitamig Is Encouraging In Triple-Negative Breast Cancer**
- Source: Citeline News & Insights | 20251209T220755 | Bullish | Relevance: 99%
- BioNTech and Bristol Myers Squibb's drug, Pumitamig, has shown promising results in treating triple-negative breast cancer. This article highlights the encouraging data for their collaborative therapeutic development.

**2. 66,361 Shares in Bristol Myers Squibb Company $BMY Bought by SVB Wealth LLC**
- Source: MarketBeat | 20251209T125009 | Somewhat-Bullish | Relevance: 99%
-  SVB Wealth LLC recently acquired 66,361 shares of Bristol Myers Squibb Company (NYSE:BMY), valued at approximately $3.07 million, contributing to institutional investors' 76.41% ownership of the company. Wall Street analysts currently hold a consensus "Hold" rating with an average target price of $55.25. The biopharmaceutical company reported strong Q3 earnings, beating expectations with $1.63 EPS and $12.22 billion in revenue, and announced a $2.48 annual dividend.

**3. Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025**
- Source: PharmiWeb.com | 20251209T003946 | Bullish | Relevance: 99%
-  Bristol Myers Squibb (BMS) is presenting new research at the 67th American Society of Hematology (ASH) Annual Meeting, highlighting advancements in lymphoma treatment. The data includes updates on targeted protein degradation agents like golcadomide and BMS-986458, alongside long-term results for the CAR T cell therapy Breyanzi®. These findings demonstrate promising efficacy and durable responses across various lymphoma types, reinforcing BMS's commitment to developing transformative therapies for patients.

**4. Leerink maintains outperform rating as Bristol Myers (BMY) expands ADEPT-2 enrollment**
- Source: MSN | 20251208T170759 | Bullish | Relevance: 99%
- Leerink has reiterated its "outperform" rating for Bristol Myers Squibb (BMY) following the company's decision to expand enrollment for its ADEPT-2 trial. This expansion signals the company's commitment to advancing its drug development pipeline.

**5. Bristol Myers Squibb (BMY) Is Up 5.1% After Expanded Breyanzi MZL Approval Has The Bull Case Changed?**
- Source: Simply Wall Street | 20251209T002246 | Bullish | Relevance: 98%
-  Bristol Myers Squibb (BMY) recently received U.S. FDA approval for its CAR T cell therapy, Breyanzi, to treat relapsed or refractory marginal zone lymphoma, broadening its patient pool and strengthening its cell therapy franchise. This approval, along with similar European expansions, aims to offset revenue pressures from impending patent cliffs on blockbuster drugs like Eliquis and Opdivo. The company's future performance hinges on successful new therapy launches and clinical trial readouts, particularly for Cobenfy.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Scotiabank | $53 | $45 | +18% |
| 2025-12-02 | Goldman Sachs | $57 | $51 | +12% |
| 2025-11-17 | Citigroup | $45 | $48 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Scotiabank | main | Sector Perform |
| 2025-12-02 | Goldman Sachs | main | Neutral |
| 2025-11-17 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (2 raises, avg +15%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $103.1B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 8.5 |
| Current P/E | 7.7 |
| YoY Growth | -8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.6% to 0.1% (-3.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 (-1.8%) diverging from MRS_10 - short-term weakness emerging. Outperforming sector by 4.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.07% (CS: 59) | Neutral |
| RSI_14 | 61.7 | Neutral |
| MACD Histogram | 0.27 | Bullish |
| vs SMA20 | 1.039x | Above |
| vs SMA50 | 1.092x | Above |
| vs SMA200 | 1.033x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $50.65
- **Stop Loss:** $48.07 (5.1% risk)
- **Target:** $53.23 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 116
- **Position Value:** $5,875.40
- **Portfolio %:** 5.88%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*